Indian listed subsidiary of Abbott selling branded generic medicines and nutrition products, made mainly for the domestic market.
Indian listed subsidiary of Abbott selling branded generic medicines and nutrition products, made mainly for the domestic market.
Earns from prescription brands that doctors recommend and patients buy again and again from pharmacies through stockists, with chronic therapies such as thyroid and stomach treatments giving steady refills. A sales force calling on doctors, not advertising, drives volume. Abbott Laboratories of the US holds the majority and supplies new products from its global range.
In one line: Abbott Laboratories' majority-owned India-listed unit.
Moat: narrow (brand, distribution). Long-standing trusted brands (Thyronorm, Digene) with entrenched doctor prescribing habits.
Headquarters: Mumbai, India · Founded: 1944 · Employees: 3,749
Size Abbott India (ABBOTINDIA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $5.80B, the 195th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹25,470 on 18 Nov 2026.
Performance Over six months the shares fell 8.4%, against -4.6% for the median peer and +3.8% for the India market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 7.2% over the last twelve months (peer median +13.4%); the operating margin is 27.7% (peer median 20.3%).
Valuation It trades at 31.1× forward earnings against a peer median of 20.4× (4th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 42.5 points above its cost of capital (9.4% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹72.0B | ₹69.3B | ₹64.1B | ₹58.5B | ₹53.5B |
| Revenue growth | — | +8% | +10% | +9% | — |
| Gross profit | ₹27.0B | ₹24.7B | ₹22.2B | ₹19.5B | ₹17.1B |
| EBITDA | ₹20.7B | ₹19.4B | ₹17.2B | ₹14.8B | ₹12.3B |
| Net income | ₹16.5B | ₹15.5B | ₹14.1B | ₹12.0B | ₹9.49B |
| Free cash flow | n/a | ₹16.6B | ₹10.8B | ₹13.1B | ₹9.61B |
| Capital expenditure | n/a | ₹409M | ₹526M | ₹483M | ₹341M |
| Total debt | ₹1.54B | ₹1.72B | ₹1.97B | ₹832M | ₹1.13B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Abbott India ABBOTINDIA.NS | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
| Pfizer PFIZER.NS | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABBOTINDIA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.7% | +1.8% | 9th lowest of 21 |
| 6-month return | -8.4% | -4.6% | 10th lowest of 20 |
| Distance from 52-week high | -16.9% | -25.4% | 6th highest of 21 |
| Revenue growth (TTM) | +7.2% | +13.4% | 7th lowest of 17 |
| Operating margin | 27.7% | 20.3% | 7th highest of 18 |
| Forward P/E | 31.1× | 20.4× | 4th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 8.0% | 1.7% | 4th most demanding of 14 |
| Growth delivered (Del g) | +10.0% | +13.9% | 5th lowest of 14 |
| Hurdle (Req g minus delivered) | -2.0 pp | -16.1 pp | 5th most demanding of 14 |
| ROIC minus cost of capital | +42.5 pp | +2.1 pp | 2nd highest of 17 |
| EV / EBITDA | 25.5× | 16.8× | 3rd most expensive of 11 |
| Net debt / EBITDA | -0.7× | 0.3× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| RemeGen 9995.HK | Hong Kong | $6.07B | -28% | +293% | 61% | 6.3× | -6.8% | +57.9% |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |